On this page of StockholderLetter.com we present the latest annual shareholder letter from KINETA, INC./DE — ticker symbol KA. Reading current and past KA letters to shareholders can bring important insights into the investment thesis.
KA Shareholder/Stockholder Letter Transcript:
Kineta, Inc. Annual Report 2023 Developing next-generation immunotherapies that address cancer immune resistance Our mission: Developing next-generation immunotherapies that address cancer immune resistance To My Fellow Shareholders, 2023 saw several major developments for the company and our programs. As the first full year as a public company, we began enrollment in our Phase 1/Phase 2 clinical program with KVA12123 for the development the treatment of solid tumor cancer. Throughout the year we reported on the progress of this program, and we presented scientific updates at a number of major cancer meetings during the year. We were pleased to have seven clinical trial sites participating in this program across the United States. In this trial we enrolled patients with advanced solid tumor cancers; a population of people that need additional therapeutic alternatives to better address the management of their disease. As we approach Kineta s second annual meeting as a public company, I want to be clear about our company, our challenges, as well as our mission. The external financing market has been challenging for Kineta and for many other biotech companies, especially smaller firms with preclinical and early clinical stage assets. In February 2024, we implemented a corporate restructuring as a result of certain investors indicating that they would not fulfill their funding obligations that had been previously committed in connection with the second tranche of the company s contemplated private placement. This restructuring resulted in a significant workforce reduction and the cessation of the enrollment of new patients into the Phase 1/Phase 2 clinical program. The company continues to assess strategic alternatives focused on maximizing shareholder value. As we progress on the evaluation of potential alternatives, we will keep you apprised of any developments and changes. On the clinical development front, we are laser focused on achieving our goal of discovering and developing next-generation immunotherapies that address cancer immune resistance. I am confident that we have the right team to move the company forward and develop innovative new products for patients with cancer. Our team at Kineta is grateful for our shareholders and recognize we could not pursue our mission without your support. We appreciate your conviction and ongoing support as we evaluate opportunities to advance the company and continue the development of KVA12123. On behalf of the Kineta team, thank you for your continued support. It is an honor to be part of Kineta as we navigate our challenges and continue to advance the development of our important clinical programs. and I am excited and optimistic about the future of the company. Craig W. Philips Craig W. Philips President4/26/2024 Letter Continued (Full PDF)